How an Activist Group Helped Torpedo MDMA Therapy
Posted inClinical Trials Drugs (Pharmaceuticals) Ethics and Official Misconduct Food and Drug Administration Institute for Clinical and Economic Review Lykos Therapeutics Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Psymposia Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

How an Activist Group Helped Torpedo MDMA Therapy

The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Posted inAlzheimer's Assn Alzheimer's Disease Amgen Inc Banner Alzheimer's Institute Biogen Inc Brain Clinical Trials Drugs (Pharmaceuticals) Eisai Co Ltd Elderly Eli Lilly and Company Food and Drug Administration Genetics and Heredity Government Accountability Office Hemorrhagic Stroke Institute for Clinical and Economic Review Kisunla Leqembi (Drug) Medicine and Health Novartis AG Retirement Communities and Assisted Living United States Villages, The (Fla)

What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
Veterans and Lawmakers Lobby for Approval of MDMA Therapy
Posted inBergman, Jack (1947- ) Clinical Trials Depression (Mental) Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration House of Representatives Institute for Clinical and Economic Review LSD (Lysergic Acid Diethylamide) Lykos Therapeutics Mental Health and Disorders Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

Veterans and Lawmakers Lobby for Approval of MDMA Therapy

The F.D.A. is poised to rule on the therapeutic use of the club drug Ecstasy, a potential watershed moment in the nascent field of psychedelic medicine.
FDA Panel Rejects Use of MDMA for Treatment of PTSD
Posted inAmerican Psychiatric Assn Drug Abuse and Traffic Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration Institute for Clinical and Economic Review Justice Department Lykos Therapeutics Medicine and Health Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Placebos Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Therapy and Rehabilitation Veterans your-feed-healthcare

FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.